Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 8.58 as of 2026-10-06T14:17:09.533Z.
Consensus retrieved: 2026-10-06T12:51:04.637Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:17:09.533Z.
Quote observation: 2026-10-06T14:15:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6807aeeb5f9368f020f59dacb006a36becc89b9769e1c9f767bbff20100e145f
Forward PE Ratio (8.58) = Dated Quote Price ($20.77) / Consensus Forward EPS ($2.42)
FORWARD PE RATIO
8.58
SECTOR MEDIAN · HEALTHCARE
19.59
median of 152 covered companies
CURRENT VS SECTOR MEDIAN
-56.20%
vs the sector median at left
Innoviva, Inc.
Market Cap
$1.53B
Forward PE Ratio
8.58
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Innoviva, Inc. (INVA) | $1.53B | 8.58 |
| Certara, Inc. (CERT)vs › | $1.51B | 28.49 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 50.08 |
| GH Research PLC (GHRS)vs › | $1.49B | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 17.72 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 7.71 |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.63B | 32.44 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.64B | N/A |
Trailing P/E
5.1
reported TTM EPS
Forward P/E
8.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.42 implies -41.0% EPS decline vs the reported trailing $4.10.
At the dated quote price of $20.77, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.42 | $2.38 – $2.46 | 4 | 8.6x |
| 2027-12-31 | $2.26 | $2.04 – $2.52 | 4 | 9.2x |
| 2028-12-31 | $1.97 | $1.69 – $2.25 | 2 | 10.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
